Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Cybin Inc (CYBN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/08/2026: CYBN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $47.46
1 Year Target Price $47.46
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -67.21% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/08/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 413.12M USD | Price to earnings Ratio - | 1Y Target Price 47.46 |
Price to earnings Ratio - | 1Y Target Price 47.46 | ||
Volume (30-day avg) 5 | Beta 0.79 | 52 Weeks Range 4.81 - 10.72 | Updated Date 01/8/2026 |
52 Weeks Range 4.81 - 10.72 | Updated Date 01/8/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.77 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.87% | Return on Equity (TTM) -52.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 309208077 | Price to Sales(TTM) 278.25 |
Enterprise Value 309208077 | Price to Sales(TTM) 278.25 | ||
Enterprise Value to Revenue 313.59 | Enterprise Value to EBITDA -3.79 | Shares Outstanding 49894131 | Shares Floating 38554692 |
Shares Outstanding 49894131 | Shares Floating 38554692 | ||
Percent Insiders 6.02 | Percent Institutions 27.08 |
Upturn AI SWOT
Cybin Inc
Company Overview
History and Background
Cybin Inc. is a biotechnology company focused on psychedelic therapeutics. Founded in 2019, the company has rapidly advanced its pipeline of psychedelic compounds and delivery mechanisms for treating mental health conditions. Key milestones include the acquisition of companies and intellectual property related to psychedelic research, strategic partnerships, and progression of its drug candidates through preclinical and early-stage clinical trials.
Core Business Areas
- Psychedelic Therapeutics Development: Cybin is engaged in the research, development, and commercialization of novel psychedelic therapeutics and drug discovery platforms for the treatment of mental health conditions. This includes identifying and developing psychedelic molecules, optimizing formulations, and conducting clinical trials.
- Delivery and Digital Therapeutics: The company is also exploring innovative delivery systems for psychedelic compounds, as well as integrating digital therapeutics to enhance patient experience and treatment outcomes.
Leadership and Structure
Cybin Inc. is led by a management team with expertise in pharmaceuticals, biotechnology, and mental health. The organizational structure is focused on research and development, clinical operations, regulatory affairs, and corporate development.
Top Products and Market Share
Key Offerings
- CYB001 (Psilocybin):: A sublingual tablet formulation of psilocybin, currently in clinical trials for major depressive disorder (MDD). Competitors include companies developing traditional antidepressants and other psychedelic-based therapies for MDD. Specific market share data for preclinical/early-stage psychedelic compounds is not yet established.
- CYB003 (Deuterated Psilocin):: A novel analog of psilocin designed for improved efficacy and safety profiles, under investigation for MDD and alcohol use disorder. Competitors include other psychedelic developers and traditional treatment providers.
- CYB004 (DMT):: Dimethyltryptamine, explored for potential therapeutic applications. Competitors are other companies researching DMT-based treatments.
Market Dynamics
Industry Overview
The psychedelic therapeutics market is a rapidly emerging and highly innovative sector within the broader mental health and pharmaceutical industries. It is characterized by significant scientific research into the therapeutic potential of psychedelics for a range of conditions, increasing regulatory interest, and substantial investment.
Positioning
Cybin is positioned as an early-mover in the development of regulated psychedelic therapeutics, focusing on proprietary compounds and innovative delivery methods. Its competitive advantages lie in its diversified pipeline, intellectual property portfolio, and strategic approach to clinical development and potential commercialization.
Total Addressable Market (TAM)
The TAM for mental health treatments, particularly for conditions like depression, anxiety, and addiction, is substantial, measured in hundreds of billions of dollars globally. Cybin is positioned to capture a portion of this market as its therapeutic candidates progress through clinical trials and gain regulatory approval.
Upturn SWOT Analysis
Strengths
- Diversified pipeline of psychedelic compounds and delivery systems.
- Proprietary intellectual property and patent portfolio.
- Experienced management team with expertise in drug development.
- Focus on regulated pathways for psychedelic therapeutics.
- Strategic partnerships and collaborations.
Weaknesses
- Early-stage clinical development with significant regulatory hurdles.
- Dependence on future funding for continued research and development.
- Limited commercialization history as a clinical-stage company.
- Challenges associated with the complex regulatory landscape for psychedelics.
Opportunities
- Growing acceptance and interest in psychedelic therapies for mental health.
- Potential for first-mover advantage in specific therapeutic areas.
- Expansion into new indications and geographic markets.
- Advancements in digital therapeutics and integrated care models.
- Potential for strategic acquisitions and partnerships.
Threats
- Regulatory delays or rejections from health authorities.
- Competition from other companies in the psychedelic space and traditional treatments.
- Challenges in scaling manufacturing and supply chain for psychedelic compounds.
- Potential changes in public perception or political landscape regarding psychedelics.
- Unforeseen clinical trial outcomes or safety concerns.
Competitors and Market Share
Key Competitors
- Compass Pathways (CMPS)
- MindMed Inc. (MNMD)
- atai Life Sciences (ATAI)
Competitive Landscape
Cybin's competitive advantages lie in its differentiated pipeline, including proprietary deuterated compounds and novel delivery systems, alongside a strong focus on regulatory pathways. However, it faces intense competition from established and emerging players in the psychedelic therapeutics space, as well as the established pharmaceutical industry for mental health treatments.
Major Acquisitions
Entheon Biomedical
- Year: 2021
- Acquisition Price (USD millions): 28.5
- Strategic Rationale: Acquisition to strengthen its psychedelic drug discovery and development capabilities, particularly in research related to psilocybin and DMT.
Isracann Biosciences Inc. (part of a broader deal structure)
- Year: 2022
- Acquisition Price (USD millions): 10
- Strategic Rationale: Strategic investment to advance research and development of novel psilocybin-based therapeutic candidates.
Growth Trajectory and Initiatives
Historical Growth: Cybin's historical growth has been characterized by rapid pipeline expansion, strategic acquisitions of intellectual property and research assets, and successful fundraising rounds to support its development activities.
Future Projections: Future growth projections are contingent on the successful completion of clinical trials, regulatory approvals, and market penetration of its therapeutic candidates. Analyst estimates are typically focused on the potential market size and Cybin's ability to capture market share.
Recent Initiatives: Recent initiatives include advancing its lead drug candidates (CYB001 and CYB003) into later-stage clinical trials, expanding its patent portfolio, and exploring novel drug delivery systems and digital therapeutics.
Summary
Cybin Inc. is a promising, albeit early-stage, player in the burgeoning psychedelic therapeutics market. Its strength lies in its diversified pipeline of proprietary compounds and innovative delivery methods, coupled with a clear strategy for navigating regulatory pathways. The company needs to carefully manage its R&D expenditures and secure adequate funding to advance its drug candidates through clinical trials and overcome the significant hurdles inherent in drug development. Continued progress in clinical outcomes and strategic partnerships will be crucial for its long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry research reports
- Financial news outlets
- Biotechnology databases
Disclaimers:
This information is for informational purposes only and does not constitute investment advice. Financial data and market share are estimates and subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cybin Inc
Exchange NYSE MKT | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2019-09-13 | Co-Founder, Interim CEO, President & Executive Chairman Mr. Eric So L.L.B. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 50 | Website https://cybin.com |
Full time employees 50 | Website https://cybin.com | ||
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.